Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Bioorg Chem. 2018 Oct 23;82:290–305. doi: 10.1016/j.bioorg.2018.10.044

Fig. 4.

Fig. 4.

Effect of compounds on BRAF-mutant A375 melanoma cell line A. 6 and 3b inhibited Elk and p90RSK phosphorylation in the BRAF-mutant A375 melanoma cell line. A375 melanoma cells were treated with a DMSO control, different concentrations of 6 or 3b (0.5–25 μM) for 12 h in serum free media. The MAP kinase pathway was then induced by the addition of EGF (100 nM) for 15 min before lysing the cells. Lysates were fractionated by SDS PAGE (10% gel) and subjected to western blot analysis in order to detect the phosphorylated forms of p-90RSK, ELK, ERK, MEK½ and JNK. B. 6 is a more potent inhibitor of A375 melanoma cell viability than 3b. Cells were treated with different doses of each inhibitor and incubated for 72 h before analysis by the MTS assay. C. Compounds 6 and 3b inhibited BRAF-mutant A375 cells anchorage-dependent growth in a dose dependent manner (Cells were treated as described in the methods section).